Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Urology

Building Your Care Team and Preparing for Visits

At a Glance

A well-coordinated prostate cancer team can help compare surgery, radiation, active surveillance, and other options. Bring original scans, biopsy material, PSA results, and treatment records so each specialist can review the same information.

Because prostate cancer is often slow-growing, you usually have the time to build a team that fits your specific needs. Your “care team” is not just one doctor, but a group of specialists who look at your cancer from different angles to ensure you are not overtreated or undertreated [1].

The Core Specialists

Each member of your team has a specific role in your journey:

  • Urologist / Urologic Oncologist: A surgeon who specializes in the urinary tract and male reproductive system. They perform biopsies, manage active surveillance, and perform surgeries like radical prostatectomy [2].
  • Radiation Oncologist: A doctor who uses high-energy beams or radioactive seeds to treat cancer. They help you understand if radiation is a better fit for your lifestyle and risk level than surgery [2].
  • Medical Oncologist: This specialist typically joins the team if the cancer has spread (metastatic disease) or if it returns after initial treatment. They manage systemic treatments like hormone therapy, chemotherapy, and targeted drugs [1].
  • Genitourinary (GU) Pathologist: This is the “doctor’s doctor” who looks at your tissue samples under a microscope. An expert GU pathologist is vital for accurately identifying the Grade Group and checking for high-risk features like cribriform pattern [3][4].
  • Nurse Navigator / Specialist Nurse: Often your most frequent point of contact, they help coordinate appointments, manage side effects, and provide emotional support [5].

Why “Volume” and Outcomes Matter

In prostate cancer care, experience is often evaluated by looking at a center’s outcomes. Rather than relying on a single fixed number of procedures per year, ask about risk-adjusted, disease-specific outcomes for patients like you [6].

For surgery, experienced centers often track [7][8]:

  • Lower Positive Margin Rates: This means they are more likely to remove all the cancer during surgery. A positive margin raises recurrence risk, though it does not by itself prove residual cancer is left behind [9].
  • Functional Recovery: Surgeons may use “nerve-sparing” techniques primarily intended to preserve erectile function, provided it doesn’t compromise cancer control. Continence depends on other anatomy, technique, and patient factors [10][11].
  • Fewer Complications: Experienced centers typically have lower rates of readmission and surgical complications [7].

For radiation, you should look for centers that use daily image guidance (to track the prostate’s position) and have their treatment plans “peer-reviewed” by other experts to minimize long-term bowel and bladder side effects [12][13].

The Power of a Tumor Board

A multidisciplinary tumor board is a formal meeting where surgeons, radiation oncologists, pathologists, and radiologists sit in one room to discuss complex cases [14]. This collaborative review can lead to changes in staging or treatment plans in a meaningful minority of cases, ensuring that no single specialist’s bias dictates your care [15][16].

Preparing for Your Consultation

When you go for a first visit or a second opinion, your team needs more than just your word. You should arrange for the transfer of these “artifacts” [17][18]:

  1. Imaging: Request secure electronic transfer of your actual images (DICOM files) for your multiparametric MRI or PSMA PET/CT so the team’s radiologist can review them [19].
  2. Pathology Slides: If you are getting a second opinion, you can request the original “glass slides” from the lab that did your biopsy. Expert GU pathologists often see things differently than general pathologists [4].
  3. PSA History: A complete list of every PSA test you have ever had, including the dates. (Note: While PSA doubling time can be useful in recurrence, a rapid rise alone does not independently determine management) [18].
  4. Treatment Summary: A list of medications, radiation summaries, or surgical reports [17].

Having these items ready allows your doctors to spend the appointment discussing your options rather than hunting for your data.

Common questions in this guide

Which specialists may be part of my prostate cancer care team?
Your team may include a urologist or urologic oncologist, a radiation oncologist, a medical oncologist, a genitourinary pathologist, and a nurse navigator. The right mix depends on whether your cancer is localized, has returned, or has spread, as well as the treatments you are considering.
What should I bring to a prostate cancer second-opinion visit?
Ask your current care team to send the actual imaging files, such as multiparametric MRI or PSMA PET/CT images, along with your pathology reports and original biopsy slides when available. Also bring a complete PSA timeline, medication list, radiation or surgical reports, and other treatment summaries.
How can I compare prostate cancer treatment centers?
Ask for risk-adjusted, disease-specific outcomes from patients with a similar cancer profile rather than relying only on a procedure-volume number. For surgery, ask about positive margins, functional recovery, readmissions, and complications; for radiation, ask about daily image guidance and review of treatment plans by other specialists.
What does a multidisciplinary tumor board do for prostate cancer?
A tumor board brings surgeons, radiation oncologists, pathologists, and radiologists together to review a complex case. This shared review can sometimes change the cancer staging or treatment plan and helps reduce reliance on one specialist’s perspective.
Why might my biopsy be reviewed by a genitourinary pathologist?
A genitourinary pathologist specializes in cancers of the urinary and male reproductive systems. Reviewing the biopsy can help confirm the Grade Group and identify features such as a cribriform pattern that may affect how risk and treatment options are considered.
How can I prepare for my first prostate cancer consultation?
Send your records before the appointment so the team can review your scans, pathology, PSA history, and treatment information in advance. Write down your priorities and questions, and ask who to contact between visits if you have urgent concerns or side effects.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you share your risk-adjusted outcomes for patients with my specific disease profile, particularly regarding surgical margins or biochemical control?
  2. 2.Will my case be formally discussed in a multidisciplinary tumor board where surgeons, radiation oncologists, and pathologists all review my data together?
  3. 3.For radiation, what specific techniques do you use to minimize long-term bowel and bladder side effects?
  4. 4.Who is my primary point of contact (such as a nurse navigator) if I have urgent questions between my visits or during my recovery?
  5. 5.Do you have a dedicated genitourinary pathologist who will review my biopsy slides to confirm the Grade Group and check for high-risk features?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.

    Zhu S, Chen J, Ni Y, et al.

    The Prostate 2021; (81(11)):721-727 doi:10.1002/pros.24167.

    PMID: 34028061
  2. 2

    Prostate cancer.

    Rebello RJ, Oing C, Knudsen KE, et al.

    Nature reviews. Disease primers 2021; (7(1)):9 doi:10.1038/s41572-020-00243-0.

    PMID: 33542230
  3. 3

    Histopathology of Prostate Cancer.

    Humphrey PA

    Cold Spring Harbor perspectives in medicine 2017; (7(10)) doi:10.1101/cshperspect.a030411.

    PMID: 28389514
  4. 4

    True Papillae and Squamous Features in Prostate Carcinoma Represent a Potential Diagnostic Pitfall: Report of 3 Patients.

    Grypari IM, Pomoni A, Ganetsou D, et al.

    International journal of surgical pathology 2026; (34(6)):1610-1615 doi:10.1177/10668969261436403.

    PMID: 41917793
  5. 5

    A Vanguard Approach to the Design and Delivery of Nurse-Led Survivorship Care.

    Sara SAM, Chambers SK, Briggs R, et al.

    Seminars in oncology nursing 2023; (39(1)):151366 doi:10.1016/j.soncn.2022.151366.

    PMID: 36411123
  6. 6

    A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.

    Van den Broeck T, Oprea-Lager D, Moris L, et al.

    European urology 2021; (80(5)):531-545 doi:10.1016/j.eururo.2021.04.028.

    PMID: 33962808
  7. 7

    Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care.

    Gershman B, Meier SK, Jeffery MM, et al.

    The Journal of urology 2017; (198(1)):92-99 doi:10.1016/j.juro.2017.01.067.

    PMID: 28153509
  8. 8

    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.

    Gray WK, Day J, Briggs TWR, Harrison S

    BJU international 2022; (129(1)):93-103 doi:10.1111/bju.15516.

    PMID: 34133832
  9. 9

    Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration.

    Bravi CA, Dell'Oglio P, Piazza P, et al.

    European urology oncology 2024; (7(4)):821-828 doi:10.1016/j.euo.2023.11.006.

    PMID: 38036328
  10. 10

    Predictors of Long-Term Urinary Incontinence After Robot-Assisted Laparoscopic Prostatectomy.

    Yamashita K, Kijima Y, Sekido E, et al.

    Research and reports in urology 2023; (15()):387-393 doi:10.2147/RRU.S419903.

    PMID: 37638328
  11. 11

    Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study.

    Godtman RA, Persson E, Cazzaniga W, et al.

    PloS one 2021; (16(6)):e0253081 doi:10.1371/journal.pone.0253081.

    PMID: 34138904
  12. 12

    ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.

    Salembier C, Villeirs G, De Bari B, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018; (127(1)):49-61 doi:10.1016/j.radonc.2018.01.014.

    PMID: 29496279
  13. 13

    ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer.

    Ghadjar P, Fiorino C, Munck Af Rosenschöld P, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2019; (141()):5-13 doi:10.1016/j.radonc.2019.08.027.

    PMID: 31668515
  14. 14

    A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.

    Holmes A, Kelly BD, Perera M, et al.

    World journal of urology 2021; (39(2)):297-306 doi:10.1007/s00345-020-03265-1.

    PMID: 32500304
  15. 15

    Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.

    Woo S, Tong A, Becker AS, et al.

    European radiology 2026; (36(6)):5068-5081 doi:10.1007/s00330-025-12301-w.

    PMID: 41493546
  16. 16

    Comparative study between 68 Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.

    Wong HS, Leung J, Bartholomeusz D, et al.

    Journal of medical imaging and radiation oncology 2018; (62(6)):816-822 doi:10.1111/1754-9485.12791.

    PMID: 30152050
  17. 17

    Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

    Scher HI, Morris MJ, Stadler WM, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(12)):1402-18 doi:10.1200/JCO.2015.64.2702.

    PMID: 26903579
  18. 18

    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

    Cornford P, van den Bergh RCN, Briers E, et al.

    European urology 2024; (86(2)):148-163 doi:10.1016/j.eururo.2024.03.027.

    PMID: 38614820
  19. 19

    Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

    Gillessen S, Bossi A, Davis ID, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (185()):178-215 doi:10.1016/j.ejca.2023.02.018.

    PMID: 37003085

This page is for informational purposes only and does not constitute medical advice. Your urologist and oncology team can interpret your records and recommend the best options for your prostate cancer.

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.